CURRENT AFFAIRS

Detailed explanation-1: -India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India’s (DCGI ) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).

Detailed explanation-2: -The Serum Institute of India (SII), in partnership with the Department of Biotechnology, New Delhi, announced the launch of its ‘home-made’ cervical cancer vaccine, CERAVANAC qHPV, last month.

Detailed explanation-3: -Meanwhile, India’s first indigenously developed vaccine to prevent cervical cancer, CERVAVAC, is all set to be available later this year, costing between ₹200-400 a shot. CERVAVAC will be effective against at least four variants of Human Papilloma Virus (HPV).

Detailed explanation-4: -The cervical cancer vaccine, Quadrivalent Human Papillomavirus vaccine (qHPV), is developed by the Serum Institute of India (SII) and the Department of Biotechnology(DBT).

Detailed explanation-5: -The quadrivalent Human Papilloma Virus (qHPV) vaccine is India’s first homemade vaccine against cervical cancer and has demonstrated a robust antibody response. The response, according to news agency PTI, is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.